NCT03503344View on ClinicalTrials.gov

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2027

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaPSA ProgressionStage IV Prostate Adenocarcinoma AJCC v7
Interventions
DRUG

Apalutamide

Given PO, 240 mg per day (4 x 60mg tablets)

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

94115

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

University of California, San Francisco

OTHER